Solventum Co. (NYSE:SOLV) Receives $79.86 Average PT from Analysts

Solventum Co. (NYSE:SOLV) has received a consensus recommendation of “Hold” from the eleven analysts that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $79.86.

Several equities research analysts have recently issued reports on SOLV shares. Bank of America lifted their price objective on shares of Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research report on Wednesday, February 26th. The Goldman Sachs Group boosted their price target on shares of Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a research note on Monday, March 3rd. Mizuho raised their price objective on Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research report on Monday, March 3rd. Wells Fargo & Company boosted their target price on Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Friday, February 28th. Finally, Morgan Stanley lifted their price objective on Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 5th.

Solventum Stock Performance

NYSE:SOLV opened at $74.78 on Wednesday. The stock has a 50-day moving average price of $75.51 and a 200 day moving average price of $71.83. The stock has a market capitalization of $12.94 billion and a P/E ratio of 27.19. Solventum has a 12-month low of $47.16 and a 12-month high of $85.92. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45.

Institutional Trading of Solventum

Institutional investors have recently bought and sold shares of the stock. Worldquant Millennium Advisors LLC raised its stake in shares of Solventum by 373.6% in the third quarter. Worldquant Millennium Advisors LLC now owns 47,665 shares of the company’s stock valued at $3,323,000 after acquiring an additional 37,600 shares during the period. Harbor Capital Advisors Inc. grew its holdings in Solventum by 24.8% during the 4th quarter. Harbor Capital Advisors Inc. now owns 46,965 shares of the company’s stock valued at $3,103,000 after purchasing an additional 9,333 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in Solventum by 37.4% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 117,853 shares of the company’s stock worth $8,217,000 after purchasing an additional 32,051 shares during the period. State Street Corp lifted its stake in Solventum by 3.1% in the third quarter. State Street Corp now owns 6,107,550 shares of the company’s stock worth $425,818,000 after purchasing an additional 185,938 shares during the last quarter. Finally, Forsta AP Fonden purchased a new position in shares of Solventum during the fourth quarter valued at approximately $1,876,000.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.